Annual report pursuant to Section 13 and 15(d)

Note 8 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss) (Details Textual)

v3.21.2
Note 8 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss) (Details Textual) - USD ($)
$ / shares in Units, $ in Thousands
 12 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2019
Common Stock, Dividends, Per Share, Declared (in dollars per share) $ 1.28 $ 1.28 $ 1.28
Stock Repurchased During Period, Shares (in shares) 120,000 279,381  
Stock Repurchased During Period, Average Share Price (in dollars per share) $ 359.81 $ 179.37  
Interest Expense, Total $ 13,952 $ 19,197 $ 21,705
Nonoperating Income (Expense), Total (89,121) 119,058 (34,704)
Deferred Income Tax Expense (Benefit), Total (28,013) 13,607 $ (14,021)
Changzhou Eminence Biotechnology [Member]      
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Noncontrolling Interest 103    
AOCI Attributable to Parent [Member]      
Deferred Income Tax Expense (Benefit), Total (1,908) $ (4,058)  
Reclassification out of Accumulated Other Comprehensive Income [Member] | AOCI Attributable to Parent [Member]      
Interest Expense, Total 8,598    
Nonoperating Income (Expense), Total 512    
Reclassification from AOCI, Current Period, Tax, Total $ 2,150